The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
Dizziness, headaches, confusion, fatigue, blurry vision and sensitivity to light are among the most common symptoms of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback